Infokiri

Dear Colleagues,

Following up on our previous email regarding the preparation of a Rapid Communication addressing the recent upsurge in cases in the European Region, we are extending the timeframe for submitting details of interested participants until EOD February 16, 2024. If your country is interested in participating, kindly provide the required information outlined in the previous communication by the updated deadline. Thank you to all who have responded so far.  

As previously communicated, we are inviting countries that have reported mpox cases through TESSy since August 2022 to participate in this peer-reviewed Rapid Communication. Please note that we will limit the number of co-authors to one to two persons per country, with the possibility of including additional colleagues in the acknowledgements section.

If your country is interested to participate, please let us know who the contributors will be, their full affiliation and a declaration that the co-authors have no conflict of interest regarding the publication of this manuscript using the table below.

Please send your reply directly to [email protected] and [email protected].

Thank you for your interest and continued collaboration.

Best regards,

The WHO EURO and ECDC mpox teams

Dear Colleagues,

WHO Regional Office for Europe and ECDC would firstly like to thank you for submitting national case-based mpox data to TESSy on a monthly basis. This data has been critical to support global situational analysis and to guide public health actions at national, regional and global levels.

In light of the recent upsurge in cases in the European Region, we are currently analyzing TESSy data with the aim of preparing a Rapid Communication (target journal: Eurosurveillance). The aim of this manuscript is to provide an overview of the recent epidemiological situation covering the period from August 2022 to February, and will build on the previous manuscript, the quarterly regional EURO/ECDC surveillance report and other global WHO outputs.

We would hereby like to invite countries who reported mpox cases through TESSy since August 2022 to participate in the preparation of this peer-reviewed Rapid Communication. We will limit the number of co-authors to a one to two persons per country, but there will be the possibility to include further colleagues in the acknowledgements. 

If your country is interested to participate, please let us know who the contributors will be, their full affiliation and a declaration that the co-authors have no conflict of interest regarding the publication of this manuscript by sending us the below table filled out at your earliest convenience and latest by Wednesday 14 February 2024 EOB. Please send your reply directly to [email protected] and [email protected].

The contributors will be expected to be available for data checks, to critically revise the results of the analysis and to review and comment on the various versions of the manuscript with short deadlines in the next 3 to 4 weeks. All authors need to meet the ICMJE authorship criteria.

In advance of the next reporting deadline on 8 February 2024, countries are requested to ensure adequate completeness of the mandatory TESSy variables, including key demographic, clinical and exposure variables. In addition to the data submitted through TESSy, we also invite any information you may have on significant mpox-related events, such as localized increases (an unexpected rise in cases in a specific city, province or region), clusters of cases linked to a gathering event (especially gatherings with international participation), nosocomial outbreaks, and other events considered significant by Member States.

In summary:

1. Please ensure completeness for key variables in next TESSy report on Thursday 8 February 2024

2. If you are interested in participating in this manuscript, please complete the table above with two co-authors from your country (deadline Wednesday 14 February 2024 EOB) and share with WHO and ECDC email addresses above.

3. Co-authors to be available for data checks, results analysis and manuscript review over next 3-4 weeks.

Please do not hesitate to contact us if you have any questions at [email protected] and [email protected].

Best regards,

The WHO EURO and ECDC teams